Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook For Reata's Bardoxolone Improves With Phase II Updates

Executive Summary

Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).

You may also be interested in...



Reata Expands Options For Bardoxolone With New CKD Data

Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab

The latest US drug development news and highlights from our Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel